Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous MTP-131 on Reperfusion Injury in Patients Undergoing Primary Percutaneous Coronary Intervention and Stenting for ST-segment Elevation Myocardial Infarction Infarction

NCT01572909 is registered in ClinicalTrials.gov with Stealth BioTherapeutics Inc. as lead sponsor.

NCT NCT01572909
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01572909 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous MTP-131 on Reperfusion Injury in Patients Undergoing Primary Percutaneous Coronary Intervention and Stenting for ST-segment Elevation Myocardial Infarction Infarction
Lead sponsor
Stealth BioTherapeutics Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2012
Completion date
February 28, 2015
Enrollment
300 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

reperfusion injury, stemi